172 lines
57 KiB
HTML
172 lines
57 KiB
HTML
|
<!DOCTYPE html>
|
|||
|
|
<html lang="" xml:lang="" xmlns="http://www.w3.org/1999/xhtml"><head>
|
|||
|
|
<meta charset="utf-8"/>
|
|||
|
|
<meta content="pandoc" name="generator"/>
|
|||
|
|
<meta content="width=device-width, initial-scale=1.0, user-scalable=yes" name="viewport"/>
|
|||
|
|
<title>19 December, 2023</title>
|
|||
|
|
<style>
|
|||
|
|
code{white-space: pre-wrap;}
|
|||
|
|
span.smallcaps{font-variant: small-caps;}
|
|||
|
|
span.underline{text-decoration: underline;}
|
|||
|
|
div.column{display: inline-block; vertical-align: top; width: 50%;}
|
|||
|
|
div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
|
|||
|
|
ul.task-list{list-style: none;}
|
|||
|
|
</style>
|
|||
|
|
<title>Covid-19 Sentry</title><meta content="width=device-width, initial-scale=1.0" name="viewport"/><link href="styles/simple.css" rel="stylesheet"/><link href="../styles/simple.css" rel="stylesheet"/><link href="https://unpkg.com/aos@2.3.1/dist/aos.css" rel="stylesheet"/><script src="https://unpkg.com/aos@2.3.1/dist/aos.js"></script></head>
|
|||
|
|
<body>
|
|||
|
|
<h1 data-aos="fade-down" id="covid-19-sentry">Covid-19 Sentry</h1>
|
|||
|
|
<h1 data-aos="fade-right" data-aos-anchor-placement="top-bottom" id="contents">Contents</h1>
|
|||
|
|
<ul>
|
|||
|
|
<li><a href="#from-preprints">From Preprints</a></li>
|
|||
|
|
<li><a href="#from-clinical-trials">From Clinical Trials</a></li>
|
|||
|
|
<li><a href="#from-pubmed">From PubMed</a></li>
|
|||
|
|
<li><a href="#from-patent-search">From Patent Search</a></li>
|
|||
|
|
</ul>
|
|||
|
|
<h1 data-aos="fade-right" id="from-preprints">From Preprints</h1>
|
|||
|
|
<ul>
|
|||
|
|
<li><strong>Are we done with Hydroxychloroquine for COVID-19? Studies with ethical, legal, and methodological concerns must now be retracted</strong> -
|
|||
|
|
<div>
|
|||
|
|
On October 30th, a new study from the Institut Hospitalo-Universitaire Méditerranée Infection (IHU-MI) was published in the journal “New Microbes and New Infections” [1]. This is the latest publication in a long series that is controversial both scientifically and legally. Indeed, several other articles had been published by this team on the topic of Covid-19. The first one [2], has been adjudicated to be fraudulent by the former President of the board of this institute [3]. Further COVID-19 research has had significant ethical concerns arise, regarding the conduct of the studies [4,5,6,7,8] due to their purported retrospective nature despite the trial description appearing to be a prospective trial. These trials are also prima facie problematic because, from May the 11th 2020 and the removal of a special decree authorizing it temporarily, the use of hydroxychloroquine was forbidden outside of clinical trials in France, and these were not conducted as clinical trials. Similarly, off-label prescription was not possible in that case because this process is subject to a strict law regulation in France and can be proposed to patients only if: i) there is no alternative labeled therapy, ii) it is used case by case and not systematically for all patients as was the case at the IHU and iii) the available scientific data ensures efficacy and safety of the drug in the dedicated indication (see Code de la Santé Publique, Article L5121-12-1-2), which was clearly not the case for hydroxychloroquine in COVID-19 treatment. Consequently, since hydroxychloroquine is considered in this indication as an experimental drug in France, a retrospective design likely contravenes French law on biomedical research (see Code de la santé publique, Article L1121-1) [9]. Despite all scientific and ethics arguments having been brought to the attention of the editor, and the publisher themselves declaring that the study has no scientific merit and is “fully irresponsible” [10] even prior to the fraud being uncovered, the initial publication has still not been retracted [11].
|
|||
|
|
</div>
|
|||
|
|
<div class="article-link article-html-link">
|
|||
|
|
🖺 Full Text HTML: <a href="https://osf.io/vhr7s/" target="_blank">Are we done with Hydroxychloroquine for COVID-19? Studies with ethical, legal, and methodological concerns must now be retracted</a>
|
|||
|
|
</div></li>
|
|||
|
|
<li><strong>Should we publish every correlation during the COVID-19 pandemic?</strong> -
|
|||
|
|
<div>
|
|||
|
|
Recently, Sun et al. published an article in Scientific Reports entitled: “Increased emergency cardiovascular events among under-40 population in Israel during vaccine rollout and third COVID-19 wave” [2]. In this paper, the authors highlighted correlations between the Israeli vaccine campaign and an increased number of severe cardiovascular event calls to Emergency Management Services in the under-40 population. Even if the correlation seemed statistically significant, it is, to our opinion, clinically irrelevant.
|
|||
|
|
</div>
|
|||
|
|
<div class="article-link article-html-link">
|
|||
|
|
🖺 Full Text HTML: <a href="https://osf.io/zj4xr/" target="_blank">Should we publish every correlation during the COVID-19 pandemic?</a>
|
|||
|
|
</div></li>
|
|||
|
|
<li><strong>When scientific journals disseminate pseudoscience</strong> -
|
|||
|
|
<div>
|
|||
|
|
We alert in this position paper the scientific community against the dissemination of pseudoscience in apparently sane scientific journals, and the dangers that such a spreading are causing to public health. Seneff et al. recently published in Food & Chemical Toxicology a series of fallacious arguments against Covid-19 vaccination. The important shortcomings and misusage of scientific literature and data have no place in a scientific journal. Therefore, we explain why this article should be retracted in an effort to prevent further damages to health care policies.
|
|||
|
|
</div>
|
|||
|
|
<div class="article-link article-html-link">
|
|||
|
|
🖺 Full Text HTML: <a href="https://osf.io/n4eu5/" target="_blank">When scientific journals disseminate pseudoscience</a>
|
|||
|
|
</div></li>
|
|||
|
|
<li><strong>Reply to “Innate immune suppression by SARS-CoV-2 mRNA vaccinations: The role of G-quadruplexes, exosomes, and MicroRNAs”: Important concerns on the validity of this article.</strong> -
|
|||
|
|
<div>
|
|||
|
|
We share a Letter of concern To the Editor from Food and Chemical Toxicology about a recent published review from Seneff. et al entitled “Innate immune suppression by SARS-CoV-2 mRNA vaccinations: The role of G-quadruplexes, exosomes, and MicroRNAs”( doi: 10.1016/j.fct.2022.113008). In our opinion, this article contains several assumptions and misinformation that we highlight. We believe that a rapid analysis of the key points and the misinterpretations that they contain are sufficient to invalidate the relevancy of the article and therefore we ask the editor to revise their opinion on the publication of the article.
|
|||
|
|
</div>
|
|||
|
|
<div class="article-link article-html-link">
|
|||
|
|
🖺 Full Text HTML: <a href="https://osf.io/m58yh/" target="_blank">Reply to “Innate immune suppression by SARS-CoV-2 mRNA vaccinations: The role of G-quadruplexes, exosomes, and MicroRNAs”: Important concerns on the validity of this article.</a>
|
|||
|
|
</div></li>
|
|||
|
|
<li><strong>Evolving spike-protein N-glycosylation in SARS-CoV-2 variants</strong> -
|
|||
|
|
<div>
|
|||
|
|
It has been three years since SARS-CoV-2 emerged and the world plunged into a “once in a century” pandemic. Since then, multiple waves of infection have swept through the human population, led by variants that were able to evade any acquired immunity. The co-evolution of SARS-CoV-2 variants with human immunity provides an excellent opportunity to study the interaction between viral pathogens and their human hosts. The heavily N-glycosylated spike-protein of SARS-CoV-2 plays a pivotal role in initiating infection and is the target for host immune response, both of which are impacted by host-installed N-glycans. We compared the N-glycan landscape of recombinantly expressed, stabilized, soluble spike-protein trimers representing seven of the most prominent SARS-CoV-2 variants and found that N-glycan processing is conserved at most sites. However, in multiple variants, processing of N-glycans from high mannose- to complex-type is reduced at sites N165, N343 and N616, implicated in spike-protein function.
|
|||
|
|
</div>
|
|||
|
|
<div class="article-link article-html-link">
|
|||
|
|
🖺 Full Text HTML: <a href="https://www.biorxiv.org/content/10.1101/2023.05.08.539897v2" target="_blank">Evolving spike-protein N-glycosylation in SARS-CoV-2 variants</a>
|
|||
|
|
</div></li>
|
|||
|
|
<li><strong>COVID-19 and socioeconomic context in Bangladesh: Discussion from a gendered point of view</strong> -
|
|||
|
|
<div>
|
|||
|
|
The COVID-19 affected communities and the economy beyond public health. The epidemic is expected to increase global poverty and inequality, making it crucial to study its effects. Several international organisations determined that a “new recession” was underway due to the global pandemic’s destructive effects on the financial, social, and personal spheres. Despite their best efforts, many undeveloped nations are fighting the pandemic’s aftereffects. Bangladesh is like other nations. Global economic and social changes will lead to new difficulties in the near future. Thus, studying COVID’s effects from a variety of perspectives, including gender, is crucial and timely. This paper explores the aftermath of the epidemic, focusing on the plight of women workers. In doing so, it sheds light on a particularly marginalised group, including maids and housekeepers, who have been denied benefits and recognition for their job.
|
|||
|
|
</div>
|
|||
|
|
<div class="article-link article-html-link">
|
|||
|
|
🖺 Full Text HTML: <a href="https://osf.io/puxk2/" target="_blank">COVID-19 and socioeconomic context in Bangladesh: Discussion from a gendered point of view</a>
|
|||
|
|
</div></li>
|
|||
|
|
<li><strong>The COVID-19 impact on tuberculosis incidence notification in India- A comparative study (2017-2022)</strong> -
|
|||
|
|
<div>
|
|||
|
|
Abstract - Despite modern drugs treatment with 60 years of chemotherapy and 90 years of vaccination with various strategies to prevent and control tuberculosis (TB), globally TB ranks 13th in leading causes of mortality. In recent year 2021 Worldwide, TB ranks 2nd after COVID-19, in leading causes of infectious killer, killing about 1.6 million people in 2021 (including 187 000 people infected with HIV). During COVID-19 era 2020, very significant global reduction in TB incidence was detected, which suddenly reduced from 7.1 million in 2019, to 5.8 million in 2020 (–18 percent). Globally, India is listed among the top three countries accounting for 67percent of this global reduction in TB incidence, besides Indonesia and the Philippines. As per data of The World Bank, India’s annual TB incidence was falling continuously since 2000, rose again and reached 210/100,000 in 2021 from 204/100,000 in 2020. A modelling analysis study found that lockdown has induced 80 percent reduction in TB notification rates in India. India ranks fourth in infection and death from COVID-19; hence there is a possibility that slowing down of COVID-19 will unmask the TB cases and deaths leading to increase in the count of TB in future years. In spite of several similarities in manifestation and differences in aetiology, there is still lack of full knowledge about the epidemiological relationship between TB and COVID-19 .To know the real situation and scenario of TB cases this study was started with aim to alert policy maker for needful action to control TB effectively in time. This study aimed to know the impact of COVID-19 on annual TB notifications incidence in India. This is a cross-sectional, quantitative, retrospective, deductive study. This research study included all the 36 states and UTs of India. We performed a linear regression study of the existing data of pre pandemic years included in this study for calculating a counterfactual analysis in order to find out the possible real incidence of TB cases notifications, which may have been notified if the current natural intervention of COVID-19 had not taken place. The annual number of new (TB) cases detected during the pre-COVID-19 period as well as COVID-19 period of this study has shown similar trends separately. During both periods the number of new (TB) cases increased in consecutive years. Another significant finding of this study is that the number of new (TB) cases detected during the first two COVID-19 years i.e. 2020 and 2021 decreased in comparison to last pre-COVID-19 year i.e. 2019. The base year of this study i.e. 2017 are having least whereas the last year of this study i.e. 2022 are having the largest number of new (TB) cases detected in one individual year. There is an increase of 7.79 percent in TB case detection during the COVID-19 period of this study. This study revealed that during first COVID-19 year i.e. 2020 there is significant reduction in number of new (TB) cases detected by 580869 numbers or 24.29 percent in comparison to last pre-COVID-19 year i.e. 2019. The number of new (TB) cases detected increased continuously during pre-COVID-19 years by 29.59 percent in 2018 and 18.49 percent in 2019. The question arises from this study is that, is it possible to achieve the goal of NTEP by year 2025 in current scenario reality?
|
|||
|
|
</div>
|
|||
|
|
<div class="article-link article-html-link">
|
|||
|
|
🖺 Full Text HTML: <a href="https://osf.io/wucgb/" target="_blank">The COVID-19 impact on tuberculosis incidence notification in India- A comparative study (2017-2022)</a>
|
|||
|
|
</div></li>
|
|||
|
|
<li><strong>What is the impact of COVID-19 pandemic years on Deliveries and Home Based New Born Care in India? A cross-sectional comparative research study, Jan 2018-2021Dec</strong> -
|
|||
|
|
<div>
|
|||
|
|
Even before the ongoing COVID-19 pandemic era, an estimated 2.8 million PW (pregnant women) and new born died every year, or 1 every 11 seconds, mostly of preventable causes. There is need of immediate investment in health workers capacity building, equipment, medicines to ensure that every mother and new born is in safe pair of hands who are able to prevent and treat complications of and during pregnancy, delivery and birth. Every year 25 million children are born in India accounting for one fifth of the global child births and every minute one baby dies. It is a fact that 46 per cent of all maternal mortality and 40 per cent of neonatal mortality happen during labour or in the first 24 hours after birth. The COVID-19 pandemic caused by SARS-CoV-2 has led to disruption of health services globally. I assessed the effect of the ongoing pandemic on the Deliveries and Home Based New Born Care (HBNC) in India. The author is curious and suspects a rise in maternal and neonatal mortality due to possible negative effects of COVID-19 on maternal institutional delivery and HBNC. Hence author decided to find out answer to the research question mentioned as title above. I conducted a retrospective cross-sectional comparative study among total numbers of women and newborn who have received delivery and HBNC care at different health facilities in 36 states and union territories across India during the pandemic years with pre-pandemic years (comparing 2020 and 2021(forecasted up to December 2021 with available data from January2021 to May 2021) with previous two years of pre-pandemic era i.e. 2018-2019). The data for the research study is extracted from electronic records of HMIS (health management information system) of MoHFW (ministry of health and family welfare), Govt. of India and analysed with stata and Microsoft office. The mean number of home deliveries attended by SBA [(Skill Birth Attendant) (Doctor/Nurse/ANM/ Midwife)] during the pandemic year 2021 with total number of observation of 5 months of 2021(January to May) forecasted up to December 2021 across India was 13370.27938, for years 2020, 2019, 2018 it was 16429.25, 19006.58, 21317.83 respectively with total number of observation of 12 months across India for these three years. This research study revealed that pandemic years have negative impact on number of home deliveries attended by SBA [(Skill Birth Attendant) (Doctor/Nurse/ANM/ Midwife)]. This research study revealed that pandemic years have negative impact on number of home deliveries attended by SBA [(Skill Birth Attendant) (Doctor/Nurse/ANM/ Midwife)]. There is a (projected) decrease of 37.28% in mean number of home deliveries attended by SBA in 2021 as compared to 2018. This novel research study revealed that during pandemic years 2020 and 2021 all the variables reduced quantitatively except Number of PW given Tablet Misoprostol during HD which increased in 2020 (first pandemic year).The ongoing COVID-19 pandemic has had negative effects on Deliveries and Home Based New Born Care (HBNC) in India. More research is required to investigate the direct and indirect consequence of the pandemic on birth and provision of HBNC as well as the health facility type which are not performing well in providing respectful maternity care and newborn services during pandemic period. The facility based research analysis is under process by the author which will be available in next version of this article. Keywords: Home delivery, Institutional delivery, new born, care, pandemic year, covid-19,
|
|||
|
|
</div>
|
|||
|
|
<div class="article-link article-html-link">
|
|||
|
|
🖺 Full Text HTML: <a href="https://osf.io/vxe49/" target="_blank">What is the impact of COVID-19 pandemic years on Deliveries and Home Based New Born Care in India? A cross-sectional comparative research study, Jan 2018-2021Dec</a>
|
|||
|
|
</div></li>
|
|||
|
|
<li><strong>What is the impact of COVID-19 pandemic years on Deliveries and Home Based New Born Care in India?</strong> -
|
|||
|
|
<div>
|
|||
|
|
Background: The COVID-19 pandemic caused by SARS-CoV-2 has led to disruption of health services globally. I assessed the effect of the ongoing pandemic on the Deliveries and Home Based New Born Care (HBNC) in India. The author is curious and suspects a rise in maternal and neonatal mortality due to possible negative effects of COVID-19 on maternal institutional delivery and HBNC. Hence author decided to find out answer to the research question mentioned as title above. Methods: I conducted a retrospective cross-sectional comparative study among total numbers of women and newborn who have received delivery and HBNC care at different health facilities in 36 states and union territories across India during the pandemic years with pre-pandemic years (comparing 2020 and 2021(up to May) with previous two years of pre-pandemic era i.e. 2018-2019). The data for the research study is extracted from electronic records of HMIS (health management information system) of MoHFW (ministry of health and family welfare), Govt. of India and analysed with stata and Microsoft office. Results: The mean number of home deliveries attended by SBA [(Skill Birth Attendant) (Doctor/Nurse/ANM/ Midwife)] during the pandemic year 2021 with total number of observation of 5 months across India was 15491, for years 2020, 2019,2018 it was 16429.25 ,19006.58 , 21317.83 respectively with total number of observation of 12 months across India for these three years. This research study revealed that pandemic years have negative impact on number of home deliveries attended by SBA [(Skill Birth Attendant) (Doctor/Nurse/ANM/ Midwife)]. This research study revealed that pandemic years have negative impact on number of home deliveries attended by SBA [(Skill Birth Attendant) (Doctor/Nurse/ANM/ Midwife)]. There is a decrease of 27.33 % in mean number of home deliveries attended by SBA in 2021 as compared to 2018. Conclusions: The ongoing COVID-19 pandemic has had negative effects on Deliveries and Home Based New Born Care (HBNC) in India. More research is required to investigate the direct and indirect consequence of the pandemic on birth and provision of HBNC as well as the health facility type which are not performing well in providing respectful maternity care and newborn services during pandemic period. The facility based research analysis is under process by the author which will be available in next version of this article. Keywords: Home delivery, Institutional delivery, newborn, care, pandemic year, covid-19
|
|||
|
|
</div>
|
|||
|
|
<div class="article-link article-html-link">
|
|||
|
|
🖺 Full Text HTML: <a href="https://osf.io/zkavs/" target="_blank">What is the impact of COVID-19 pandemic years on Deliveries and Home Based New Born Care in India?</a>
|
|||
|
|
</div></li>
|
|||
|
|
<li><strong>Precaution & Safety Methods for Hospital Duty During covid-19 Pandemic Era for Healthcare Workers of Bihar, India: A protective & Supportive Approach</strong> -
|
|||
|
|
<div>
|
|||
|
|
The current ongoing coronavirus pandemic caused by SARS-CoV-2/covid-19/novel coronavirus is an acute infectious communicable disease spreading mainly via respiratory, eye, mouth and other possible routes from person to person as well as through contact with infected non living objects. Added to previous global burden of NCDs (non communicable diseases) & other communicable diseases this new pandemic burden of covid-19 pandemic have put a stress on already overstressed health system of India particularly poor states like Bihar. The delivery of health services is of utmost importance and prime concern in India particularly poor states like Bihar due to high population load with limited resources, poor infrastructure and huge demand on healthcare system. The Healthcare workers (HCWs) are particularly vulnerable group hence this topic needs essential attention and protection. The SARS-CoV-2 pandemic had presented a challenge even for developed healthcare systems around the world. A sense of fear gripped the whole world due to pandemic and India is not an exception. The scarce healthcare resources including manpower, infrastructure, transportation (ambulance services) etc. have been largely deployed to tackle the situation of pandemic of Covid-19. This shift & covid-19 pandemic has tremendous and detrimental effects on HCWs. The healthcare workers of India as well as Bihar are getting frequently infected leading to death of thousands of healthcare workers till date. Although there are several guidelines issued for precaution and safety at workplace by WHO (world Health Organization) & several accredited organizations but a protective and supportive approach from local management and governance is need of the hour. It seems that there is failure of protective and preventive measures at workplace documented and evidenced by several deaths of healthcare workers. Consequently it is apparent from above scenario to ensure the health and safety of healthcare workers in order to control the outbreak and decrease panic and fear among healthcare workers. In this article I am sharing methods and various ways for protecting healthcare workers (HCWs) while having hospital duties as well as policy makers and management people can also find this article useful while making policies for protecting and safeguarding HCWs. This article aims to reduce incidence/prevalence as well as mortality and morbidity of HCWs in Bihar by suggesting important precautions, preventive measures and other facts to be adopted by healthcare workers at workplace as well as drawing attention of policy maker, important stakeholders and management people to provide protection to HCWs.
|
|||
|
|
</div>
|
|||
|
|
<div class="article-link article-html-link">
|
|||
|
|
🖺 Full Text HTML: <a href="https://osf.io/ygaun/" target="_blank">Precaution & Safety Methods for Hospital Duty During covid-19 Pandemic Era for Healthcare Workers of Bihar, India: A protective & Supportive Approach</a>
|
|||
|
|
</div></li>
|
|||
|
|
<li><strong>What is the impact of COVID-19 era on annual tuberculosis notifications in India? A comparative study (2017-2022)</strong> -
|
|||
|
|
<div>
|
|||
|
|
Globally Tuberculosis (TB) is 13th leading cause of mortality and the 2nd leading infectious killer after COVID-19, 1.6 million people died in 2021 from TB (including 187 000 people with HIV). The emergence of COVID-19 pandemic situations on the already overburdened health care system of India may have affected new TB cases notification as well as treatment, setting back the previous achievements made to eliminate TB by 2025. Lockdown-induced under-reporting (80% reduction in TB notification rates) of active TB will affect TB epidemiology as well as NTEP (National Tuberculosis Elimination Program) elimination goal by 2025. There are significant studies which found that COVID-19 is promoting the growth of active tuberculosis in a patient with dormant/latent tuberculosis infection. In the COVID-19 epidemic, diagnosis and treatment of tuberculosis, or tuberculosis and the co-infection with COVID-19, may be compromised as TB and COVID-19 both present with respiratory symptoms that are similar to each other. According to the 2019 India TB Report, 2, 24,000 incident cases per year of paediatric TB are estimated accounting for 22% of global burden. In spite of many similarities and differences, there is still a lack of clarity about the exact epidemiological relationship between COVID-19 and TB. This was a cross-sectional, retrospective, quantitative; research study aimed to know the impact of COVID-19 era on TB (tuberculosis) notifications in India (includes all 36 states and UTs of India). All the 36 participants’ states and UTs newly detected tuberculosis cases notifications were followed from 1st January 2017 to 31st December 2022. The total number of newly detected tuberculosis cases notifications from 1st January 2017 to 31st December 2022 was 12290180 (n) including all 36 participants. The (period prevalence) total number of newly detected tuberculosis cases notifications during pre-COVID-19 era (2017-2019) was 5914621 and during the COVID-19 era (2020-2022) were 637559. The total annual newly detected tuberculosis cases notifications (including public and private healthcare facilities) in India including all 36 participants from beginning of year 1st January till 31st December during a year were 1525045, 1997873, 2391703, 1810834, 2145678, 2419047, for years 2017, 2018, 2019, 2020, 2021, and 2022 respectively. The mean of newly detected tuberculosis cases notifications from all public and private healthcare facilities during Pre-COVID-19 era (2017-2019) was 164295 (Std. Err. - 37404.92; [95% Conf. Interval] - 88359.01- 240231; Std. Dev. - 224429.5). The mean of newly detected tuberculosis cases notifications from all public and private healthcare facilities during COVID-19 era (2020-2022) was 177098.9 (Std. Err. - 43081.17; [95% Conf. Interval] - 89639.43 -264558.3; Std. Dev. - 258487). The incidence rate of newly detected tuberculosis cases notifications per lakh population was 112.62; 145.94; 172.92; 129.68; 152.44; and 169.63 respectively for years 2017, 2018, 2019, 2020, 2021, 2022. This research study revealed that the incidence rate of newly detected tuberculosis cases notifications per lakh population kept on increasing during the pre-COVID-19 era and it decreased abruptly during the first COVID-19 year 2020 by 25.00 percent (%) compared to previous year of pre-COVID-19 era 2019.
|
|||
|
|
</div>
|
|||
|
|
<div class="article-link article-html-link">
|
|||
|
|
🖺 Full Text HTML: <a href="https://osf.io/tvby7/" target="_blank">What is the impact of COVID-19 era on annual tuberculosis notifications in India? A comparative study (2017-2022)</a>
|
|||
|
|
</div></li>
|
|||
|
|
<li><strong>What is the impact of the COVID-19 pandemic epoch on IPD (Inpatient Department) hospital admissions in India- A 41months comparative, quantitative, deductive Cross-Sectional Research Study?</strong> -
|
|||
|
|
<div>
|
|||
|
|
Abstract - The inpatient department or IPD is the dedicated unit of a hospital/healthcare facility for admitting patients from the OPD (outpatient department), ED (emergency department), or a referred patient usually from lower facilities for a planned care/procedure, for special medical problems that necessitate suitable care and consideration. The index case of SARS-CoV-2 virus infection in India was first suspected (based on clinical grounds) on 27th January 2020, an assumed case of covid-19 in Kerala with a current voyage history of Wuhan, china which was subsequently affirmed as SARS-CoV-2 virus infection positive case by the NIV (National Institute of Virology) situated at Pune in Maharashtra, on January 30th, 2020 as positive for COVID-19. As per the constitution of India Health is a subject matter of state, hence different states had reserved different percentages of beds in pre-existing health facilities for COVID-19 IPD patients, for example, the Delhi government had reserved 50% of pre-existing ICU (intensive care unit) and ward beds for COVID-19 IPD patient’s. Besides the other factors such as fear etc, mentioned above this new arrangement of hospital care delivery and prioritization of needs of COVID-19 patients may have resulted in the general cancellations of other IPD patients elective procedures leading to a reduced IPD number of patients with diseases other than COVID-19, as priority was shifted to COVID-19 admitted patient’s and cases. The first author researcher of this study has found unusual prevalence in the figure of IPD (Inpatient Department) hospital admissions during his normal course of duties at health centres throughout the current ongoing COVID-19(coronavirus disease-2019) era. To know about the real scenario a good sample size is a requirement for any epidemiological study. Hence this deductive study was done to confirm that, does the COVID-19 era have affected the number of IPD hospital admissions (positively or negatively). This study was started and designed to get an answer to the above question. The aim of this 41months comparative, quantitative, deductive, Cross-Sectional Research Study is to assess the direct impacts of COVID-19 on the number of IPD hospital admissions in India (other than COVID-19), across all public/private/rural/urban health facilities of 36 states and union territories registered on HMIS (Health Management Information System) of Ministry of Health and Family Welfare (MoHFW), Government of India on a cumulative basis. For the 17 months (2020-2021) COVID-19 pandemic epoch, the total mean number of IPD admissions was 5387311 compared to the total mean7435770 numbers of IPD admission for the previous pre-pandemic 2 years (2018-2019). The total mean number of IPD admission decreased by 2048459 numbers during the COVID-19 pandemic epoch i.e.27.55% decrease in IPD hospital admission observed during COVID-19. This research study revealed that there is a significant decrease in IPD hospital admissions for various medical conditions other than COVID-19 during the COVID-19 pandemic epoch which is a matter of concern for policy and decision-makers. A huge number of dead bodies were found floating in the sacred holy rivers of India (especially in the states of Bihar and Uttar Pradesh) during the ongoing COVID-19 epoch. Now it is quite possible that these dead bodies are of people with serious conditions other then COVID-19 who failed to get IPD admissions for treatment and died subsequently without treatment.
|
|||
|
|
</div>
|
|||
|
|
<div class="article-link article-html-link">
|
|||
|
|
🖺 Full Text HTML: <a href="https://osf.io/tqehr/" target="_blank">What is the impact of the COVID-19 pandemic epoch on IPD (Inpatient Department) hospital admissions in India- A 41months comparative, quantitative, deductive Cross-Sectional Research Study?</a>
|
|||
|
|
</div></li>
|
|||
|
|
<li><strong>What can be impact of civil authorities faulty mortality registration on COVID-19 mortality count in the state of Bihar, India- Evidence from NFHS-5</strong> -
|
|||
|
|
<div>
|
|||
|
|
Several local / global / national / international agencies have been estimating the impact of COVID-19 pandemic on mortality count in different regions. On 30 January 2020 the World Health Organization (WHO) declared COVID-19 a Public Health Emergency of International Concern (PHEIC). Death toll was only 171 on 30-01-2020 and by 31 -12- 2020, this figure increased to 1 813 188. The estimates of global deaths attributable to the COVID-19 pandemic in 2020 as published by WHO is at least 3 million, which is 1.2 million more than officially reported. Objective of this research study is to find out number of deaths in the household in the three years preceding the survey registered with the civil authorities’ with another objective of this research study is to estimate the excess mortality due to COVID-19 in a simple way to be understood by most of the readers. The total sample size was 35,834 households, 42,483 women of age 15-49 (including 6,350 women interviewed in PSUs in the state module), and 4,897 men of age 15-54 for the state of Bihar. This sample size was based on the size needed to produce reliable indicator estimates for each district. Household questionnaire regarding number of deaths in the household in the three years preceding the survey were collected and utilized to produce information in 19 languages using CAPI (Computer Assisted Personal Interviewing). This cross sectional survey study revealed that only 37.1 percent of deaths of households members due to any cause were registered with the civil authorities in the three years preceding the survey, of which 28 percent of deaths are at age 0-4, 45 percent of deaths occurred at age 25-34, and 41 percent of deaths occurred at age 35 and above (see table-1 and 2 for more details).
|
|||
|
|
</div>
|
|||
|
|
<div class="article-link article-html-link">
|
|||
|
|
🖺 Full Text HTML: <a href="https://osf.io/tk74d/" target="_blank">What can be impact of civil authorities faulty mortality registration on COVID-19 mortality count in the state of Bihar, India- Evidence from NFHS-5</a>
|
|||
|
|
</div></li>
|
|||
|
|
<li><strong>Impact of COVID-19 induced lockdown on the OPD patients of Diabetes, Hypertension, Stroke (CVA), Acute Heart Disease, Mental Illness, Epilepsy, Ophthalmic, Dental and oncology in India- A Cross-Sectional Research Study</strong> -
|
|||
|
|
<div>
|
|||
|
|
Abstract - The First global covid-19 patient was reported from Wuhan city in China (Hubei Province) during December 2019. India’s first suspected patient of SARS-CoV-2 infection was reported on 27th of January 2020, from Kerala state, which had a travel history of Wuhan city in china. This suspected case was tested and reported as the first covid-19 positive case by the (NIV) National Institute of Virology, Pune, on January 30, 2020. The government of India like other global countries responded to this novel disease by enforcing complete nationwide lockdown starting on 25/03/2020 and ending on 31/05/2020. In this cross-sectional research study, I had done assessment of the impact of covid-19 induced lockdown on OPD patients of few non communicable diseases (NCD). The data for different quantitative variables were collected for 12 months before and after lockdown, observed, analysed for the years 2019, 2020, 2021. The complete lockdown period of April-May 2020 is compared with the previous 12 months of lockdown (including period of March 2020 which had only last 7 days of complete lockdown) as well as later 12 months. Also the lockdown months (April-May-2020) were compared to previous (April-May-2019) as well as next (April-May-2021) year same months. Here the researcher would like to emphasize that different months of years may have different numbers of patients due to seasonal and geographical variations in prevalence of diseases. The researcher had included the month of March 2020 in order to show the trends of OPD numbers to closest timeline before the lockdown. The OPD (outpatient Department) services for the patients of significant NCD burden such as Diabetes, Hypertension, Stroke (CVA), Acute Heart Disease, Mental Illness, Epilepsy, Ophthalmic, Dental and oncology were selected for this study-analysis to assess the difference between pre and post intervention (lockdown). The author previous preprints on this research study are mentioned in note and acknowledgement. This research study revealed that COVID-19 induced lockdown period have negative impact on NCD (non-communicable disease) - OPD health services utilization. Non-communicable diseases are the major burden of disease in India as well as at global levels. The researcher had done this study to draw the attention of policy makers and governments to give more attention on emphasis and priority for NCDs care in any situations of emergency like pandemic and natural calamities, lockdowns etc which usually disrupt routine healthcare. Routine healthcare is very essential and significant in context of chronic diseases which can be converted to acute emergency conditions like CVA due to lack of care and proper-timely treatments.
|
|||
|
|
</div>
|
|||
|
|
<div class="article-link article-html-link">
|
|||
|
|
🖺 Full Text HTML: <a href="https://osf.io/qbg45/" target="_blank">Impact of COVID-19 induced lockdown on the OPD patients of Diabetes, Hypertension, Stroke (CVA), Acute Heart Disease, Mental Illness, Epilepsy, Ophthalmic, Dental and oncology in India- A Cross-Sectional Research Study</a>
|
|||
|
|
</div></li>
|
|||
|
|
<li><strong>What is the impact of Covid-19 on the Antenatal Care Services Utilization in Public-Private-Rural-Urban Hospitals of India during the COVID-19 Pandemic Period of 2020-2021 compared to pre-pandemic era 2018-2019?</strong> -
|
|||
|
|
<div>
|
|||
|
|
Background The ongoing coronavirus (COVID-19) pandemic is well documented to have a disastrous effect on the health-care services, particularly pregnancy-related health services. In order to provide the information to the scientific community and policy makers with accredited evidence and data in the country, this retrospective cross sectional mixed research study aims to find out the impact of the COVID-19 pandemic on antenatal services utilization among pregnant women of India attending public / private / rural / urban health facilities in 36 states and union territories. Hence, the researcher hopes that result and analysis will be beneficial to important stakeholders as well as policy makers in designing strategies for prioritizing pregnancy healthcare even within the ongoing COVID-19 pandemic period. Methods A facility-based retrospective mixed cross-sectional study was conducted from 1st January 2018 to 31st May 2021 for pregnant women attending public / private / rural / urban ANC services in 36 states and union territories of India. A total of 96990524 women registered for ANC during this period across all health facilities were included in the study with a purposive sampling technique. The data required for this study is collected from HMIS of Ministry of Health and Family Welfare (MoHFW) which is the most accredited data source in India. The total number of indicators included for the study was 20.The data collected is analysed with the help of Microsoft office. Results Overall, 96990524 women registered for ANC during the study period. The analysis shows that the covid-19 pandemic era has a negative impact on several indicators. The study revealed that there is significant increase in ANC service utilization at urban health facility of all the services as compared to pre-pandemic era on cumulative all India basis. Conclusion Enhancing women knowledge of protective health services, prioritizing maternal care related health services during ongoing COVID-19, and improving the accessibility of ANC service should be emphasized for getting maximum benefit to the neediest. Keywords: antenatal care, health facility, utilization, coronavirus disease, pregnant women, India
|
|||
|
|
</div>
|
|||
|
|
<div class="article-link article-html-link">
|
|||
|
|
🖺 Full Text HTML: <a href="https://osf.io/q7pgv/" target="_blank">What is the impact of Covid-19 on the Antenatal Care Services Utilization in Public-Private-Rural-Urban Hospitals of India during the COVID-19 Pandemic Period of 2020-2021 compared to pre-pandemic era 2018-2019?</a>
|
|||
|
|
</div></li>
|
|||
|
|
</ul>
|
|||
|
|
<h1 data-aos="fade-right" id="from-clinical-trials">From Clinical Trials</h1>
|
|||
|
|
<ul>
|
|||
|
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Restoring Energy With Sub-symptom Threshold Optimized Rehabilitation Exercise for Long COVID</strong> - <b>Conditions</b>: Long Covid19; Exercise Intolerance, Riboflavin-Responsive <br/><b>Interventions</b>: Behavioral: Restoring Energy with Sub-symptom Threshold Aerobic Rehabilitation Exercise; Behavioral: Light Stretching/Breathing Exercises <br/><b>Sponsors</b>: Columbia University; New York University <br/><b>Recruiting</b></p></li>
|
|||
|
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>A Pilot Study of Liraglutide (A Weight Loss Drug) in High Risk Obese Participants With Cognitive and Memory Issues</strong> - <b>Conditions</b>: Multiple Sclerosis; Long COVID; Long Covid19; Obese; Obesity; Obesity, Morbid; Acute Leukemia in Remission <br/><b>Interventions</b>: Drug: Liraglutide Pen Injector [Saxenda]; Other: Medication Diary <br/><b>Sponsors</b>: University of Chicago <br/><b>Not yet recruiting</b></p></li>
|
|||
|
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>A Phase 1 Trial of Recombinant COVID-19 Trivalent Protein Vaccine （CHO Cell）LYB002V14 in Booster Vaccination</strong> - <b>Conditions</b>: SARS-CoV-2; COVID-19 Vaccine <br/><b>Interventions</b>: Biological: 30μg dose of LYB002V14; Biological: 60μg dose of LYB002V14; Biological: placebo <br/><b>Sponsors</b>: Guangzhou Patronus Biotech Co., Ltd.; Yantai Patronus Biotech Co., Ltd. <br/><b>Not yet recruiting</b></p></li>
|
|||
|
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>EXERCISE TRAINING USING AN APP ON PHYSICAL CARDIOVASCULAR FUNCTION INDIVIDUALS WITH POST-COVID-19 SYNDROME</strong> - <b>Conditions</b>: Post-Acute COVID-19 Syndrome <br/><b>Interventions</b>: Behavioral: Exercise; Behavioral: Control <br/><b>Sponsors</b>: University of Nove de Julho <br/><b>Not yet recruiting</b></p></li>
|
|||
|
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>COVID-19 Vaccine Effectiveness Against Recurrent Infection Among Lung Cancer Patients and Biomarker Research</strong> - <b>Conditions</b>: COVID-19 Recurrent; Lung Cancer; Vaccination; Antibody; Chemotherapy; Immune Checkpoint Inhibitor <br/><b>Interventions</b>: Biological: Any Chinese government-recommended COVID-19 booster vaccine <br/><b>Sponsors</b>: Peking Union Medical College Hospital <br/><b>Recruiting</b></p></li>
|
|||
|
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>IMMUNERECOV CONTRIBUTES TO IMPROVEMENT OF RESPIRATORY AND IMMUNOLOGICAL RESPONSE IN POST-COVID-19 PATIENTS.</strong> - <b>Conditions</b>: Long Covid19; Dietary Supplements; Respiratory Tract Infections; Inflammation <br/><b>Interventions</b>: Dietary Supplement: Nutritional blend (ImmuneRecov). <br/><b>Sponsors</b>: Federal University of São Paulo <br/><b>Recruiting</b></p></li>
|
|||
|
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Physical Activity Coaching in Patients With Post-COVID-19</strong> - <b>Conditions</b>: Post-COVID-19 Syndrome <br/><b>Interventions</b>: Behavioral: Self-monitoring; Behavioral: Goal setting and review; Behavioral: Education; Behavioral: Feedback; Behavioral: Contact; Behavioral: Exercise; Behavioral: Report; Behavioral: Social support; Behavioral: Group activities; Behavioral: World Health Organization recommendations for being physically active <br/><b>Sponsors</b>: University of Alcala; Professional College of Physiotherapists of the Community of Madrid <br/><b>Not yet recruiting</b></p></li>
|
|||
|
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Study on Post-Acute COVID-19 Syndrome in Improvement of COVID-19 Rehabilitated Patients by Respiratory Training</strong> - <b>Conditions</b>: COVID-19, Post-Acute COVID-19 Syndrome, Dyspnea, Incentive Spirometer <br/><b>Interventions</b>: Device: breathing training <br/><b>Sponsors</b>: Tri-Service General Hospital <br/><b>Active, not recruiting</b></p></li>
|
|||
|
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Low-intensity Aerobic Training Associated With Global Muscle Strengthening in Post-COVID-19</strong> - <b>Conditions</b>: COVID-19 <br/><b>Interventions</b>: Procedure: muscle strengthening <br/><b>Sponsors</b>: Centro Universitário Augusto Motta <br/><b>Completed</b></p></li>
|
|||
|
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Ensitrelvir for Viral Persistence and Inflammation in People Experiencing Long COVID</strong> - <b>Conditions</b>: Long COVID; Post Acute Sequelae of COVID-19; Post-Acute COVID-19 <br/><b>Interventions</b>: Drug: Ensitrelvir; Other: Placebo <br/><b>Sponsors</b>: Timothy Henrich; Shionogi Inc. <br/><b>Not yet recruiting</b></p></li>
|
|||
|
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Intravenous Immunoglobulin Replacement Therapy for Persistent COVID-19 in Patients With B-cell Impairment</strong> - <b>Conditions</b>: COVID-19 <br/><b>Interventions</b>: Drug: Immunoglobulins <br/><b>Sponsors</b>: Jaehoon Ko <br/><b>Not yet recruiting</b></p></li>
|
|||
|
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Effect of Inhaled Hydroxy Gas on Long COVID Symptoms</strong> - <b>Conditions</b>: Post-Acute COVID-19 Syndrome <br/><b>Interventions</b>: Device: Hydroxy gas <br/><b>Sponsors</b>: Oxford Brookes University <br/><b>Recruiting</b></p></li>
|
|||
|
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Community Care Intervention to Decrease COVID-19 Vaccination Inequities</strong> - <b>Conditions</b>: COVID-19 Vaccination <br/><b>Interventions</b>: Behavioral: Community Health Worker Intervention to Enhance Vaccination Behavior (CHW-VB) <br/><b>Sponsors</b>: RAND; Clinical Directors Network; National Institute on Minority Health and Health Disparities (NIMHD) <br/><b>Recruiting</b></p></li>
|
|||
|
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>PROmotion of COVID-19 BOOSTer VA(X)Ccination in the Emergency Department - PROBOOSTVAXED</strong> - <b>Conditions</b>: COVID-19 <br/><b>Interventions</b>: Behavioral: Vaccine Messaging; Behavioral: Vaccine Acceptance Question <br/><b>Sponsors</b>: University of California, San Francisco; National Institute of Allergy and Infectious Diseases (NIAID); Pfizer; Duke University; Baylor College of Medicine; Thomas Jefferson University <br/><b>Not yet recruiting</b></p></li>
|
|||
|
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Stem Cell Study for Long COVID-19 Neurological Symptoms</strong> - <b>Conditions</b>: Post-Acute COVID-19 Syndrome <br/><b>Interventions</b>: Biological: Stem Cell <br/><b>Sponsors</b>: Charles Cox; CBR Systems, Inc. <br/><b>Not yet recruiting</b></p></li>
|
|||
|
|
</ul>
|
|||
|
|
<h1 data-aos="fade-right" id="from-pubmed">From PubMed</h1>
|
|||
|
|
<ul>
|
|||
|
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Inhibition of SARS-CoV-2 NSP-15 by Uridine-5’-Monophosphate Analogues Using QSAR Modelling, Molecular Dynamics Simulations, and Free Energy Landscape</strong> - SARS-CoV-2 is accountable for severe social and economic disruption around the world causing COVID-19. Non-structural protein-15 (NSP15) possesses a domain that is vital to the viral life cycle and is known as uridylate-specific endoribonuclease (EndoU). This domain binds to the uridine 5’-monophosphate (U5P) so that the protein may carry out its native activity. It is considered a vital drug target to inhibit the growth of the virus. Thus, in this current study, ML-based QSAR and virtual…</p></li>
|
|||
|
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Human super antibody to viral RNA-dependent RNA polymerase produced by a modified Sortase self-cleave-bacteria surface display system</strong> - CONCLUSION: The functionalized super antibody to RNA virus RdRp was successfully produced by using combined Sortase self-cleave and bacterial surface display systems with modification. The display system is suitable for downstream processing in a large-scale production of the super antibody. It is applicable also for production of other recombinant proteins in soluble free-folding form.</p></li>
|
|||
|
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Contemporary Public Health Finance: Varied Definitions, Patterns, and Implications</strong> - The financing of public health systems and services relies on a complex and fragmented web of partners and funding priorities. Both underfunding and “dys-funding” contribute to preventable mortality, increases in disease frequency and severity, and hindered social and economic growth. These issues were both illuminated and magnified by the COVID-19 pandemic and associated responses. Further complicating issues is the difficulty in constructing adequate estimates of current public health…</p></li>
|
|||
|
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Investigation of the mutated antimicrobial peptides to inhibit ACE2, TMPRSS2 and GRP78 receptors of SARS-CoV-2 and angiotensin II type 1 receptor (AT1R) as well as controlling COVID-19 disease</strong> - SARS-CoV-2 is a global problem nowadays. Based on studies, some human receptors are involved in binding to SARS-CoV-2. Thus, the inhibition of these receptors can be effective in the treatment of Covid-19. Because of the proven benefits of antimicrobial peptides (AMPs) and the side effects of chemical drugs, they can be known as an alternative to recent medicines. RCSB PDB to obtain PDB id, StraPep and PhytAMP to acquire Bio-AMPs information and 3-D structure, and AlgPred, Toxinpred,…</p></li>
|
|||
|
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Decoy peptides effectively inhibit the binding of SARS-CoV-2 to ACE2 on oral epithelial cells</strong> - The entry of SARS-CoV-2 into host cells involves the interaction between the viral spike protein and the human angiotensin-converting enzyme 2 (ACE2) receptor. Given that the spike protein evolves rapidly to evade host immunity, therapeutics that block ACE2 accessibility, such as spike decoys, could serve as an alternative strategy for attenuating viral infection. Here, we constructed a drug screening platform based on oral epithelial cells to rapidly identify peptides or compounds capable of…</p></li>
|
|||
|
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Efficacy and safety of zapnometinib in hospitalised adult patients with COVID-19 (RESPIRE): a randomised, double-blind, placebo-controlled, multicentre, proof-of-concept, phase 2 trial</strong> - BACKGROUND: Zapnometinib is an oral, non-ATP-competitive, small-molecule inhibitor of MEK1/MEK2 with immunomodulatory and antiviral properties. We aimed to investigate the safety and efficacy of zapnometinib in patients with COVID-19.</p></li>
|
|||
|
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Design, synthesis and biological evaluation of betulinic acid derivatives as potential inhibitors of 3CL-protease of SARS-CoV-2</strong> - During the coronavirus reproduction process, 3-chymotrypsin-like protease (3CLpro) and papain-like protease (PLpro) are accountable for the fragmentation of two polyprotein precursors (pp1a/pp1ab) into substructural proteins. These two proteins are vital for the replication and transcription of the viral genome. Therefore, 3CLpro is a key protein and target for the design of coronavirus inhibitors. In previous studies, we found that betulinic acid has an inhibitory effect on 3CLpro, with 51.5 %…</p></li>
|
|||
|
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Chlorogenic acid inhibits porcine deltacoronavirus release by targeting apoptosis</strong> - Porcine deltacoronavirus (PDCoV), belonging to family Coronaviridae, genus Deltacoronavirus, can cause acute diarrhea in piglets, and also possesses cross-species transmission potential, leading to severe economic losses and threatening public health. However, no approved drug against PDCoV infection is available. Here, we investigated the antiviral effect of chlorogenic acid (CGA), the main active component of Lonicerae Japonicae Flos, against PDCoV infection. The results showed that CGA…</p></li>
|
|||
|
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Protective Efficacy of Novel Engineered Human ACE2-Fc Fusion Protein Against Pan-SARS-CoV-2 Infection In Vitro and in Vivo</strong> - Enduring occurrence of severe COVID-19 for unvaccinated, aged, or immunocompromised individuals remains an urgent need. Soluble human angiotensin-converting enzyme 2 (ACE2) has been used as a decoy receptor to inhibit SARS-CoV-2 infection, which is limited by moderate affinity. We describe an engineered, high-affinity ACE2 that is consistently effective in tissue cultures in neutralizing all strains tested, including Delta and Omicron. We also found that treatment of AC70 hACE2 transgenic mice…</p></li>
|
|||
|
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>C<sub>60</sub> -based Multivalent Glycoporphyrins Inhibit SARS-CoV-2 Specific Interaction with the DC-SIGN Transmembrane Receptor</strong> - Since WHO has declared the COVID-19 outbreak a global pandemic, nearly seven million deaths have been reported. This efficient spread of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) is facilitated by the ability of the spike glycoprotein to bind multiple cell membrane receptors. Although ACE2 is identified as the main receptor for SARS-CoV-2, other receptors could play a role in viral entry. Among others, C-type lectins such as DC-SIGN are identified as efficient trans-receptor…</p></li>
|
|||
|
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>DYRK1A is a multifunctional host factor that regulates coronavirus replication in a kinase-independent manner</strong> - Coronaviruses, like other positive-sense RNA viruses, can remodel the host membrane to form double-membrane vesicles (DMVs) as their replication organelles. Currently, host factors involved in DMV formation are not well defined. In this study, we used transmissible gastroenteritis virus (TGEV) as a virus model to investigate the regulatory mechanism of dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) on coronavirus. Results showed that DYRK1A significantly inhibited TGEV…</p></li>
|
|||
|
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Phase I study, and dosing regimen selection for a pivotal COVID-19 trial of GST-HG171</strong> - This study is aimed to evaluate the safety, tolerability, and pharmacokinetics (PK), as well as to select an appropriate dosing regimen for the pivotal clinical trial of GST-HG171, an orally bioavailable, potent, and selective 3CL protease inhibitor by a randomized, double-blind, and placebo-controlled phase I trial in healthy subjects. We conducted a Ph1 study involving 78 healthy subjects to assess the safety, tolerability, and PK of single ascending doses (150-900 mg) as well as multiple…</p></li>
|
|||
|
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Promises and Pitfalls of Calcineurin Inhibitors in COVID-19: A Systematic Review and Meta-analysis of Controlled Trials</strong> - CONCLUSION: CIs are able to inhibit the virus nucleocapsid protein so that they can prevent replication and respiratory tract tissue damage caused by SARS-CoV-2. Based on the characteristics mentioned in detail, CIs can play a potential therapeutic role for COVID-19 patients.</p></li>
|
|||
|
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>An overview of the role of Niemann-pick C1 (NPC1) in viral infections and inhibition of viral infections through NPC1 inhibitor</strong> - Viruses communicate with their hosts through interactions with proteins, lipids, and carbohydrate moieties on the plasma membrane (PM), often resulting in viral absorption via receptor-mediated endocytosis. Many viruses cannot multiply unless the host’s cholesterol level remains steady. The large endo/lysosomal membrane protein (MP) Niemann-Pick C1 (NPC1), which is involved in cellular cholesterol transport, is a crucial intracellular receptor for viral infection. NPC1 is a ubiquitous…</p></li>
|
|||
|
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Acarbose reduces Pseudomonas aeruginosa respiratory tract infection in type 2 diabetic mice</strong> - CONCLUSIONS: This study confirmed the attenuating effect of acarbose on P. aeruginosa RTIs in T2DM and nondiabetic mice and investigated its mechanism, providing novel support for its clinical application in related diseases.</p></li>
|
|||
|
|
</ul>
|
|||
|
|
<h1 data-aos="fade-right" id="from-patent-search">From Patent Search</h1>
|
|||
|
|
|
|||
|
|
|
|||
|
|
<script>AOS.init();</script></body></html>
|